Related Experiment Video
Updated: Apr 12, 2026
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
Comparison of high-resolution melting analysis, Sanger sequencing and ARMS for KRAS mutation detection in metastatic
Background:
Treatment of metastatic colon carcinoma with the anti-epidermal growth factor receptor antibody cetuximab/panitumumab is reported to be ineffective in KRAS-mutant tumors; therefore, it is necessary to perform KRAS mutation analysis before cetuximab or panitumumab treatment is initiated.
Methods:
This study was designed to compare and evaluate the efficacy of three different methodologies--high resolution melting (HRM), Sanger sequencing, and Amplification Refractory Mutation System (ARMS)--for KRAS mutation detection in a clinical setting.
Results:
In total, 55 samples from patients with metastatic colorectal cancer were analyzed. Compared to Sanger sequencing, good consistency was found between the results of the ARMS (Kappa = 0.839) and HRM (Kappa = 0.839). The sensitivities of the methods were compared after a consensus was reached: if two of the three methodologies showed a similar result, it was considered as the consensus result. The frequency of KRAS mutations in our population was 34.5%, and discordant findings were observed in five samples. No significant difference in sensitivity was found among the three methodologies.
Conclusions:
From the results, we can conclude that after careful in-laboratory validation, HRM is a good alternative to the ARMS and Sanger sequencing for KRAS mutation testing.
Insights
High-resolution melting (HRM) is a reliable method for detecting KRAS mutations in metastatic colon cancer patients. This KRAS mutation analysis is crucial for guiding treatment with anti-EGFR antibodies like cetuximab.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- KRAS mutation status is critical for predicting response to anti-EGFR therapies (cetuximab/panitumumab) in metastatic colorectal cancer.
- Tumors with KRAS mutations are generally unresponsive to these targeted treatments, necessitating accurate mutation detection.
- Pre-treatment KRAS mutation analysis is a standard requirement for patient selection.
Purpose of the Study:
- To evaluate and compare the clinical efficacy of three distinct methods for KRAS mutation detection.
- To assess High-Resolution Melting (HRM) analysis against Sanger sequencing and Amplification Refractory Mutation System (ARMS).
- To determine the most suitable method for routine KRAS mutation testing in a clinical laboratory setting.
Main Methods:
- Comparative analysis of three molecular diagnostic techniques: HRM, Sanger sequencing, and ARMS.
- Testing of 55 clinical samples from patients diagnosed with metastatic colorectal cancer.
- Establishment of a consensus result based on agreement between at least two of the three methodologies for sensitivity comparison.
Main Results:
- High concordance was observed between HRM, ARMS, and Sanger sequencing (Kappa values of 0.839 for both HRM and ARMS vs. Sanger).
- The overall frequency of KRAS mutations in the studied cohort was 34.5%.
- No statistically significant differences in sensitivity were detected among the three evaluated methods.
Conclusions:
- High-Resolution Melting (HRM) analysis demonstrates comparable performance to ARMS and Sanger sequencing for KRAS mutation detection.
- HRM offers a viable and effective alternative for KRAS mutation testing in clinical practice.
- Validated HRM assays provide reliable results for guiding anti-EGFR therapy decisions in colorectal cancer patients.
